Tuesday, November 18, 2025 11:45:25 AM
Big volume. Let's hope something is brewing
Recent NRSN News
- NeuroSense Granted Brazilian Patent Covering PrimeC Composition • PR Newswire (US) • 04/06/2026 01:20:00 PM
- NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements • PR Newswire (US) • 04/03/2026 02:02:00 PM
- NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update • PR Newswire (US) • 03/31/2026 01:20:00 PM
- NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout • PR Newswire (US) • 03/24/2026 01:00:00 PM
- /C O R R E C T I O N -- NeuroSense/ • PR Newswire (US) • 03/18/2026 02:44:00 PM
- PrimeC New Data to Be Presented at AD/PD™ 2026 Conference • PR Newswire (US) • 03/18/2026 12:00:00 PM
- JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity • PR Newswire (US) • 03/16/2026 03:33:00 PM
- PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference • PR Newswire (US) • 03/09/2026 03:07:00 PM
- NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition • PR Newswire (US) • 02/09/2026 02:20:00 PM
- World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB • PR Newswire (US) • 01/08/2026 01:45:00 PM
- NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study • PR Newswire (US) • 12/22/2025 02:17:00 PM
- NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 • PR Newswire (US) • 12/04/2025 12:30:00 PM
- NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS • PR Newswire (US) • 11/24/2025 02:56:00 PM
- NeuroSense to Host Investor Webinar on December 8, 2025 • PR Newswire (US) • 11/03/2025 02:15:00 PM
- NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers • PR Newswire (US) • 10/06/2025 01:00:00 PM
- NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons • PR Newswire (US) • 09/10/2025 06:30:00 PM
- NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price • PR Newswire (US) • 09/04/2025 12:49:00 PM
- NeuroSense Provides Business Update and Progress for the First Half of 2025 • PR Newswire (US) • 08/01/2025 01:00:00 PM
- Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community • PR Newswire (US) • 07/22/2025 12:42:00 PM
- NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch • PR Newswire (US) • 05/07/2025 12:45:00 PM
- NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update • PR Newswire (US) • 04/24/2025 01:09:00 PM
- NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment • PR Newswire (US) • 04/09/2025 12:30:00 PM
